Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Frederick Feely"'
Autor:
Kelly E. Seaton, Rachel L. Spreng, Milite Abraha, Matthew Reichartz, Michelle Rojas, Frederick Feely, Richard H. C. Huntwork, Sheetij Dutta, Sarah V. Mudrak, S. Munir Alam, Scott Gregory, Erik Jongert, Margherita Coccia, Fernando Ulloa-Montoya, Ulrike Wille-Reece, Georgia D. Tomaras, S. Moses Dennison
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-13 (2021)
Abstract RTS,S/AS01 is an advanced pre-erythrocytic malaria vaccine candidate with demonstrated vaccine efficacy up to 86.7% in controlled human malaria infection (CHMI) studies; however, reproducible immune correlates of protection (CoP) are elusive
Externí odkaz:
https://doaj.org/article/0219a60f06354a4495a0f6088c161287
Autor:
Lindsay C. Dahora, Celina Jin, Rachel L. Spreng, Frederick Feely, Ryan Mathura, Kelly E. Seaton, Lu Zhang, Jennifer Hill, Elizabeth Jones, S. Munir Alam, S. Moses Dennison, Andrew J. Pollard, Georgia D. Tomaras
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Vaccination against Salmonella Typhi using the Vi capsular polysaccharide, a T-cell independent antigen, can protect from the development of typhoid fever. This implies that antibodies to Vi alone can protect in the absence of a T cell-mediated immun
Externí odkaz:
https://doaj.org/article/e8fec64964ec415e8b5d83f1cb315fc8
Autor:
Erik Jongert, Richard H. C. Huntwork, S. Munir Alam, Milite Abraha, Sheetij Dutta, S. Moses Dennison, Rachel L. Spreng, Matthew Reichartz, Sarah V. Mudrak, Fernando Ulloa-Montoya, Georgia D. Tomaras, Michelle Rojas, Scott Gregory, Ulrike Wille-Reece, Margherita Coccia, Kelly E. Seaton, Frederick Feely
Publikováno v:
NPJ Vaccines
npj Vaccines, Vol 6, Iss 1, Pp 1-13 (2021)
npj Vaccines, Vol 6, Iss 1, Pp 1-13 (2021)
RTS,S/AS01 is an advanced pre-erythrocytic malaria vaccine candidate with demonstrated vaccine efficacy up to 86.7% in controlled human malaria infection (CHMI) studies; however, reproducible immune correlates of protection (CoP) are elusive. To iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b7dc6f86f1303f7b3321678063449c2
https://pubmed.ncbi.nlm.nih.gov/34462438
https://pubmed.ncbi.nlm.nih.gov/34462438
Autor:
M. Juliana McElrath, Ian Frank, Shuying S. Li, Peter B. Gilbert, Nicole L. Yates, Allan C. deCamp, Mengshu Shao, Scott D. Neidich, Guido Ferrari, Shelly Karuna, Chul-Woo Pyo, Lawrence Corey, Magdalena E. Sobieszczyk, Xiaoying Shen, Georgia D. Tomaras, John R. Mascola, Raphael Gottardo, Frederick Feely, Hvtn Study Team, Lu Zhang, Youyi Fong, Barney S. Graham, Bryan Blette, Brian D. Williamson, Edith Swann, Daniel E. Geraghty, William Chad Young, Holly Janes, Kelly E. Seaton, Sheetal Sawant, Scott M. Hammer, Derrick Goodman
Publikováno v:
J Clin Invest
HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered persons who have sex with men in the United States. Identified immune correlates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55ae897ec20a0c36b59c79591a71371f
https://pubmed.ncbi.nlm.nih.gov/31589166
https://pubmed.ncbi.nlm.nih.gov/31589166